## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-9.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($297.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Who Owns Amgen? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20251209T130753 | Bullish | Relevance: 100%
-  This article details the top shareholders of Amgen Inc. (NASDAQ: AMGN), primarily large institutional investors and passive funds, alongside recent adjustments by active managers and hedge funds. It also reviews recent insider trading activity, noting that sales were modest and purchases by directors appeared administrative, suggesting a neutral stance on near-term performance. The overall sentiment indicates strong long-term confidence in Amgen's cash flow durability and pipeline potential.

**2. Has the Market Fully Priced In Amgen’s Rally After Pipeline and Regulatory Milestones?**
- Source: Simply Wall Street | 20251207T030903 | Somewhat-Bullish | Relevance: 100%
-  Amgen's stock has seen significant gains, up 27.2% year to date, fueled by an expanding pipeline and regulatory milestones. Analysis using Discounted Cash Flow and Price vs. Earnings models suggests Amgen is currently undervalued. The article presents bullish and bearish narratives for Amgen, with fair value estimates ranging from $322.88 to $404.87 per share.

**3. Amgen Inc. $AMGN Shares Bought by Cerity Partners LLC**
- Source: MarketBeat | 20251207T090732 | Somewhat-Bullish | Relevance: 99%
-  Cerity Partners LLC increased its stake in Amgen Inc. by 4.2% during the second quarter, now owning 0.08% of the company's stock valued at $118.12 million. Several other hedge funds and institutional investors also adjusted their positions in Amgen, with institutional investors collectively owning 76.50% of the stock. Recent analyst ratings for Amgen are largely positive, with a "Moderate Buy" consensus and an average target price of $335.65.

**4. Fayez Sarofim & Co Acquires 18,213 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251209T103852 | Bullish | Relevance: 99%
-  Fayez Sarofim & Co has increased its stake in Amgen Inc. by 53.7%, purchasing an additional 18,213 shares in Q2, bringing their total holdings to 52,146 shares valued at $14.56 million. Amgen reported strong Q2 earnings, beating analyst estimates for EPS and revenue, and declared a quarterly dividend of $2.38 per share. Analysts generally maintain a "Moderate Buy" rating for Amgen, despite recent insider share sales.

**5. Amgen Inc. $AMGN Shares Bought by L2 Asset Management LLC**
- Source: MarketBeat | 20251208T122952 | Bullish | Relevance: 99%
-  L2 Asset Management LLC increased its stake in Amgen Inc. by 50.8% in Q2, acquiring an additional 3,314 shares, bringing their total holdings to 9,837 shares valued at $2.75 million. This comes as institutional investors now own approximately 76.5% of Amgen's stock, following the company's strong Q3 earnings beat and positive FY2025 guidance. Amgen also declared a quarterly dividend of $2.38 per share, resulting in an annual yield of about 2.9%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-9.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Forward P/E 14.4x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $169.0B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 14.4 |
| Current P/E | 14.8 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.1% to -8.8% (-9.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.8pp (needs >4.0% for momentum thesis). AM_20 at -6.8% indicates price below own 20MA trend. Underperforming sector by 4.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-4.20), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -8.77% (CS: 3) | Weak |
| RSI_14 | 39.7 | Neutral |
| MACD Histogram | -4.20 | Bearish |
| vs SMA20 | 0.931x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.057x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $313.85
- **Stop Loss:** $297.67 (5.2% risk)
- **Target:** $346.21 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 18
- **Position Value:** $5,649.30
- **Portfolio %:** 5.65%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*